EPO and chronic kidney disease: Previously, we have reported that a low dose of EPO, which did not affect the hematocrit level, attenuated endothelial dysfunction and macrophage infiltration in aortas of diabetic, hypertensive, and subtotal nephrectomized chronic kidney disease rat models [7,8,9,10,11].